Answers are grounded in this paper and cite their sources.
Observational study reveals ruxolitinib cream matches systemic biologics in reducing disease extent in moderate atopic dermatitis, suggesting an effective non-systemic treatment alternative.
PURPOSE: Ruxolitinib cream (Janus kinase [JAK]1/JAK2 inhibitor) was effective and well tolerated in clinical trials of patients with atopic dermatitis (AD). We examined real-world outcomes among patients with moderate AD treated with ruxolitinib cream or systemic therapies. METHODS: (August 2022-March 2023) were analyzed descriptively. Patients treated with ruxolitinib cream, traditional systemic immunosuppressants, oral JAK inhibitors, or biologics comprised 4 mutually exclusive cohorts. RESULTS: Among 619 patients (mean age, 39.1 y; 50% female; 79% White), mean affected body surface area (BSA) was reduced from treatment initiation by 49% with ruxolitinib cream, 35% with systemic immunosuppressants, 61% with oral JAK inhibitors, and 55% with biologics. Nearly half of patients (48.4%) had reduced physician-reported disease severity with ruxolitinib cream versus 6.3%, 51.5%, and 46.4% with systemic immunosuppressants, oral JAK inhibitors, and biologics, respectively. Results were similar among patients with baseline affected BSA ≤20%. CONCLUSIONS: Physician-reported outcomes show that ruxolitinib cream monotherapy substantially reduced the extent and severity of moderate AD, suggesting that it provides an effective topical treatment option in these specific populations.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: